|Bid||19.02 x 800|
|Ask||19.10 x 4000|
|Day's range||18.92 - 19.48|
|52-week range||18.92 - 42.50|
|Beta (3Y monthly)||1.59|
|PE ratio (TTM)||41.26|
|Earnings date||6 Aug 2019 - 12 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.56|
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
DEEP DIVE A return to stock-market volatility no doubt has many investors worried. We have seen that over long periods, low-volatility index funds have performed better than their full-index benchmarks.
Shares of Mylan N.V. sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status. Mylan's long-term issuer default rating at Fitch is BBB-, the lowest investment-grade rating. Fitch said the revised outlook reflects its expectation that gross leverage may remain elevated over the near term because of slower-than-expected revenue growth, cash generation and debt reduction. Fitch's rating and outlook is similar to S&P Global Ratings' BBB- rating with a negative outlook, while Moody's Investors Service has a Baa3 rating--one notch above "junk"--with a stable outlook. Generic drug maker stocks have been under pressure in recent weeks, and took another header on Monday after more than 40 state attorneys general filed suit against 20 makers of generic medications, alleging a conspiracy to artificially inflate prices and reduce competition. Shares of fellow generic drug maker Teva Pharmaceutical Industries Ltd. slid 6.1% in morning trade to a 1 1/2-year low. Year to date, Mylan's stock has tumbled 27.6% and Teva shares have plunged 26.2%, while the SPDR Health Care Select Sector ETF has gained 1.3% and the S&P 500 has tacked on 13.3%.
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidance for Europe and Rest of World In the first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance in the mid-single
News of China’s retaliatory tariffs sent shares tumbling. The Dow Jones Industrial Average lost 2.38% to close at 25,324.99. The S&P 500 has dropped 2.41% to finish at 2811.87, and the Nasdaq Composite dropped 3.41% to close at 7647.02.
Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)North America revenue growth trendsDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance of high-single-digits for its
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Expense guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its guidance for fiscal 2019 SG&A (selling, general, and administrative) expenses to
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Gross margin guidanceAt the Raymond James 40th Annual Institutional Investors Conference, Mylan (MYL) guided for an adjusted gross margin of 53.0% to 54.0% for fiscal 2019, a
Shares of Mylan N.V. plunged 21% on Tuesday, as the stock headed toward its steepest one-day decline in 19 years.
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Adjusted EPS guidanceDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed fiscal 2019 adjusted EPS guidance of $3.80 to $4.80, which would be a decline of
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its fiscal 2019 revenue guidance of $11.5 billion to $12.5 billion. The company expects to
Is Mylan an Attractive Pick after Q1 Results?Stock price movementsOn May 7, Mylan (MYL) reported first-quarter results. The company reported revenues of $2.50 billion, a YoY decline of 7% or around $200 million short of the consensus estimate.
Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.
Market weakness could help bring both sides back together, but if tensions corporate confidence and capital spending could take a hit.
Stocks that moved substantially or traded heavily on Tuesday: American International Group Inc., up $3.19 to $50.30 The insurer reported solid underwriting gains in the first quarter and profit beat Wall ...
Mylan, one of the world’s biggest makers of generic drugs, has faced manufacturing problems, competition and declining prices that have created “unprecedented volatility,” Chief Executive Officer Heather Bresch said on a call with investors after reporting first-quarter results. “There is a tremendous amount of work being done” by the strategic committee, which will provide an update in the “near term,” Bresch said on a conference call after the company reported first-quarter earnings. Investors, however, were in no mood to wait, and Mylan shares fell 24 percent to $21.53.
Mylan’s sales missed Wall Street targets and the company offered no update on a strategic review that’s been in progress since August. Allergan’s quarter was saved by its blockbuster Botox, which helped the company raise its full-year guidance. While both companies disappointed shareholders, it wouldn’t fair to put Allergan in the same basket as Mylan; it isn’t in quite the same dire straits.
The drugmaker's challenges in the U.S. generics market and problems at a manufacturing facility weighed on its first-quarter revenue and earnings.